top of page



APRIL 29, 2022

US-based Biotechnology company, Taiga launches breakthrough veterinary cancer treatment in Singapore

AURORA, Colo., and SINGAPORE, Singapore -- Taiga Biotechnologies, a clinical-stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease, announced today the introduction of an easy-to-use, cost-effective product, which will be offered by SustentoBio Inc., a 100% owned subsidiary of Taiga Biotechnologies, Inc. represents a significant development in immunotherapies for veterinary use for treatment of solid tumour cancers and aging.  [...]


NOVEMBER 10, 2021

Taiga Initiates Phase 1/2 Clinical Study of TBX-2400 in Acute Myeloid Leukemia and Myelofibrosis in Croatia

AURORA, Colo., and ZAGREB, Croatia -- Taiga Biotechnologies, a cell-based immunotherapy company, announced today that the Company has completed the site initiation session for the first site to participate in the TBX-2400-01 clinical trial, a Phase 1/2 study to evaluate the safety and early efficacy of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis patients undergoing hematopoietic stem cell transplant (HSCT), in Croatia. [...]


FEBRUARY 9, 2021

Taiga Treats First Cancer Patient in TBX-3400-003 Clinical Trial in Israel

AURORA, Colo. & PETACH TIQWA, Israel -- Taiga Biotechnologies, Inc., a cell-based immunotherapy company, announced today that a colorectal cancer patient at the Davidoff Cancer Center, Beilenson Hospital, Rabin Medical Center, Petach Tikva, was the first recipient of a treatment designed to treat drug-resistant solid tumors in the company's recently approved Israeli trial. [...]


JUNE 13, 2016

Taiga Biotechnologies Awarded Orphan Drug Designation for Stem Cell Therapy

AURORA, Colo. -- The Food and Drug Administration has given Taiga Biotechnologies, Inc. Orphan Drug Designation for an experimental product designed to treat children with a rare immune deficiency that forces them to live in a sterile environment. [...]


Press Releases
bottom of page